Jostein Dahle

This inventor holds 2 USPTO granted patents and 7 published patent applications, plus 1 CIPO patent and 3 EPO patents. Top assignee: Nordic Nanovector as. Active years: 2014-2016.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Jostein Dahle. Retrieved from https://idiyas.com/inventor/jostein-dahle

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 2 (Patent Applications = 7)

% Patents Active = 100.0

CIPO Patents = 1 (Patent Applications = 3)

EPO Patents = 3 (Patent Applications = 8)

Average Co-Inventor Count = 3.0

ph-index = 1

Company Filing History:

2 out of 2

Nordic Nanovector as

patents

Years Active: 2014-2016

Loading Chart...

2 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 9358309 - Radioimunoconjugates and uses thereof (2016-06-07),

2. 8628749 - Radioimmunoconjugates and uses thereof (2014-01-14),

Title: Jostein Dahle: Innovator in Radioimmunoconjugates

Introduction

Jostein Dahle is a notable inventor based in Haslum, Norway. He has made significant contributions to the field of cancer treatment through his innovative work on radioimmunoconjugates. With a total of 2 patents, Dahle's inventions focus on advancing therapeutic options for B cell malignancies.

Latest Patents

Dahle's latest patents include groundbreaking work on radioimmunoconjugates that specifically bind to human CD37. These inventions encompass pharmaceutical compositions and their applications in treating cancer, particularly targeting B cell malignancies. His research aims to enhance the efficacy of cancer treatments and improve patient outcomes.

Career Highlights

Throughout his career, Jostein Dahle has been associated with Nordic Nanovector, where he has contributed to the development of innovative cancer therapies. His work has been pivotal in advancing the understanding and application of radioimmunoconjugates in clinical settings.

Collaborations

Dahle has collaborated with esteemed colleagues such as Roy Hartvig Larsen and Øyvind S Bruland. These partnerships have fostered a collaborative environment that encourages innovation and the sharing of ideas in the field of cancer research.

Conclusion

Jostein Dahle's contributions to the field of radioimmunoconjugates represent a significant advancement in cancer treatment. His innovative patents and collaborations highlight his commitment to improving therapeutic options for patients facing B cell malignancies.

Profile summary based on public USPTO records.